• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Cardiology

Transcatheter aortic valve replacement effective for high-risk and inoperable patients with severe aortic stenosis [PARTNER 1 and PARTNER 2 trials]

byDevin MillerandXiaozhou Liu
March 18, 2015
in Cardiology, Surgery
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

1. [PARTNER 1 trial] Transcatheter aortic valve replacement (TAVR) in high-risk surgical patient was shown to have similar outcomes as surgical aortic valve replacement therapy (SAVR).

2. [PARTNER 2 trial] TAVR proved to be more effective than standard treatment for patients with inoperable aortic stenosis.

Evidence Rating Level: 1 (Excellent)

Study Rundown: Aortic stenosis is a common form of heart disease among the elderly. If left untreated the disease leads to hemodynamic instability and is often fatal. Treatment of the condition eventually requires making the decision whether or not to pursue surgical intervention. In many patients this decision is complex given that the elderly are most affected by the condition and are often times questionable surgical candidates. Transcatheter aortic valve replacement (TAVR) is a less invasive option for individuals requiring aortic valve replacement but not suited to traditional surgical aortic valve replacement (SAVR). Results of two related trials on the subject were published in Lancet. The authors of these studies sought to determine how TAVR compares with SAVR in high-risk surgical patients (PARTNER 1 trial) and those with inoperable aortic stenosis (PARTNER 2 trial) with regards to mortality at 5 years. TAVR appeared to be superior or comparable to SAVR in most metrics, although was associated with higher mortality in certain subgroups with moderate-to-severe post-procedural aortic regurgitation (see In-Depth). These studies benefit from drawing from a large and geographically diverse patient population, thus, allowing for high degree of generalizability. It is unfortunate that one limitation to these studies was that quality of life (QOL) data was not collected after 1 year. Knowing how TAVR affects the QOL of patients in the long term compared to surgical or standard non-surgical treatment would have provided additional insight into the potential benefits of TAVR.

Both studies were funded by Edwards Lifesciences. The funder designed and monitored the study and participated in the selection and management of the study sites and data collection.

Click to read the PARTNER-1 study in Lancet

Click to read the PARTNER-2 study in Lancet

RELATED REPORTS

PI-RADS version 2: Standardized acquisition, interpretation, and reporting of prostate MRI [Classics Series]

#VisualAbstract: Capivasertib in addition to fulvestrant improves progression-free survival in ER⁺ advanced breast cancer

Tiotropium bromide safe and effective in treating early childhood wheezing

Relevant Reading: On the natural history of severe aortic stenosis

In-Depth [randomized controlled trial]: The PARTNER-1 study included 699 high surgical risk patients with severe aortic stenosis (valve area ≤0.8 cm2, and resting or inducible peak velocity ≥4 m/s or a mean valve gradient ≥ 40 mm Hg) from 25 centers from the United States, Canada, and Germany. The overall Society of Thoracic Surgeons Predicted Risk of Mortality score was 11.7% for the study population. The authors found that at 5 years post treatment all-cause mortality was 67.8% in patients receiving TAVR compared with 62.4% in patients receiving SAVR (hazard ratio 1.04, 95% CI 0.86-1.24; p=0.76). Additionally, there was no deterioration of implanted valves requiring surgical intervention in either group. Notably, at 30 days, 40 (14%) of the 280 patients in the TAVR group had moderate to severe aortic regurgitation, compared to 2 (1%) in the SAVR group (p<0.0001). Total aortic regurgitation was associated with increased 5-year mortality risk in the TAVR group (p=0.003).

The PARTNER-2 study enrolled 358 patients with inoperable aortic stenosis from the same 25 centers as with PARTNER-1. Patients were assigned to receive either TAVR treatment or standard non-surgical treatment for aortic stenosis. Risk of death was found to be 71.8% in patients receiving TAVR treatment and 93.6% in patients receiving standard treatment (HR 0.50, 95% CI 0.39-0.65; p < 0.0001). At 5 years, the risk of cardiovascular-related mortality was 57.5% in the TAVR group, compared to 85.9% in the standard treatment group (p<0.0001). The risk of stroke at 5 years was 16.0% in the TAVR group, compared to 18.2% in the standard group (HR 1.39; p=0.555). Notably, for patients with post-procedural moderate-to-severe paravalvular leak, the 5-year all-cause mortalities were not significantly different between the two groups (p=0.510).

Image: PD

©2015 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Previous Post

CT coronary angiography clarifies diagnosis in patients with suspected angina due to coronary heart disease [SCOT-HEART trial]

Next Post

2 Minute Medicine Rewind March 9 – March 15, 2015

RelatedReports

The ABCD2 score: Risk of stroke after Transient Ischemic Attack (TIA) [Classics Series]
Radiology Classics

PI-RADS version 2: Standardized acquisition, interpretation, and reporting of prostate MRI [Classics Series]

August 16, 2022
#VisualAbstract: Capivasertib in addition to fulvestrant improves  progression-free survival in ER⁺ advanced breast cancer
StudyGraphics

#VisualAbstract: Capivasertib in addition to fulvestrant improves progression-free survival in ER⁺ advanced breast cancer

August 16, 2022
Hypertonic saline may be effective in bronchiolitis
Chronic Disease

Tiotropium bromide safe and effective in treating early childhood wheezing

August 16, 2022
The ABCD2 score: Risk of stroke after Transient Ischemic Attack (TIA) [Classics Series]
Radiology Classics

Combination mammography and breast tomosynthesis improves breast cancer screening [Classics Series]

August 16, 2022
Next Post
No obesity paradox found between BMI, stroke, and death

2 Minute Medicine Rewind March 9 – March 15, 2015

Novel HCV treatment may be cost-effective for some genotypes

Novel HCV treatment may be cost-effective for some genotypes

Polyethylene glycol superior to lactulose for hepatic encephalopathy [HELP trial]

Improved hepatitis C drugs may increase healthcare costs

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • PI-RADS version 2: Standardized acquisition, interpretation, and reporting of prostate MRI [Classics Series]
  • #VisualAbstract: Capivasertib in addition to fulvestrant improves progression-free survival in ER⁺ advanced breast cancer
  • Tiotropium bromide safe and effective in treating early childhood wheezing
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.